Available treatments for COPD are mainly palliative, and there are no therapies available that halt the decline in lung function ... and LABA), long-acting muscarinic antagonists (LAMA) and ...

ICS do not improve lung function in COPD, but they may be added to LABA and/or LAMA primarily to prevent acute exacerbations of COPD. Triple Therapy. Patients with obstructive lung disease who ...

In the study Spiolto - which combines tiotropium, the active ingredient in Boehringer's LAMA drug Spiriva with LABA olodaterol - demonstrated a 42 percent improved in a key measure of lung ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...